Literature DB >> 17346523

Review of the economic and quality-of-life burden of cervical human papillomavirus disease.

Rachael L Fleurence1, Julia M Dixon, Tsveta F Milanova, Kathleen M Beusterien.   

Abstract

OBJECTIVE: The purpose of this study was to conduct a systematic literature review on the economic burden and health-related quality-of-life impact of cervical human papillomavirus disease. STUDY
DESIGN: A systematic review of cost-of-illness studies and health-related quality-of-life studies was conducted. PubMed, Embase, and PsycINFO databases were searched with the use of predefined terms.
RESULTS: Nine economic and 24 quality-of-life studies were identified. The annual health care costs of human papillomavirus-related conditions in the United States range from 2.25-4.6 billion dollars (2005 US dollars). The burden of human papillomavirus is second only to human immunodeficiency virus among sexually transmitted diseases. Health-related quality-of-life areas that are impacted substantially by human papillomavirus include emotional, social, and sexual functioning.
CONCLUSION: The economic and quality-of-life burden of cervical human papillomavirus disease is significant and highlights the need for treatment and prevention options for this condition.

Entities:  

Mesh:

Year:  2007        PMID: 17346523     DOI: 10.1016/j.ajog.2007.01.028

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

1.  Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.

Authors:  Cornelia L Trimble; Rachael A Clark; Christopher Thoburn; Nicole C Hanson; Jodie Tassello; Denise Frosina; Ferdynand Kos; Jessica Teague; Ying Jiang; Nicole C Barat; Achim A Jungbluth
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

2.  Disparities in human papillomavirus vaccine completion among vaccine initiators.

Authors:  Betty Chou; Lauren S Krill; Bernice B Horton; Christopher E Barat; Cornelia L Trimble
Journal:  Obstet Gynecol       Date:  2011-07       Impact factor: 7.661

Review 3.  TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers.

Authors:  Kelly Barrios; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2012-04-22       Impact factor: 6.968

Review 4.  The economic burden of noncervical human papillomavirus disease in the United States.

Authors:  Delphine Hu; Sue Goldie
Journal:  Am J Obstet Gynecol       Date:  2008-05       Impact factor: 8.661

5.  Qualitative study of women's anxiety and information needs after a diagnosis of cervical dysplasia.

Authors:  Gitte Lee Mortensen; Anny Lisbeth Adeler
Journal:  Z Gesundh Wiss       Date:  2010-03-31

6.  The nurse's role in the prevention of cervical cancer among underserved and minority populations.

Authors:  Norma Martinez Rogers; Adelita G Cantu
Journal:  J Community Health       Date:  2009-04

7.  Prevalence of high-risk human papillomavirus among older women.

Authors:  Stacy Tessler Lindau; Melinda L Drum; Elyzabeth Gaumer; Hanna Surawska; Jeanne A Jordan
Journal:  Obstet Gynecol       Date:  2008-11       Impact factor: 7.661

Review 8.  The cost effectiveness of human papillomavirus vaccines: a systematic review.

Authors:  Katherine Seto; Fawziah Marra; Adam Raymakers; Carlo A Marra
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

9.  Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.

Authors:  Mohsen Khatibi; Hamid Reza Rasekh
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

10.  Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran.

Authors:  Mohsen Khatibi; Hamid Reza Rasekh; Zohreh Shahverdi; Hamid Reza Jamshidi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.